Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22
No trades
No trades
Compare with Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22
5.43 CAD
4.40 M CAD
1.45 M CAD
1.31 M
Company info
Sector
Industry
CEO
Louis Michael Kovacs
Website
Headquarters
Oakville
Founded
2017
IPO date
Nov 23, 2017
ISIN
CA08934P2070
CUSIP
08934P207
FIGI
BBG00JCCV0Y6
Identifiers
ISIN CA08934P2070
Big Pharma Split Corp. provides investment services. It invests in equity securities with focus on pharmaceutical industry. The company was founded on September 15, 2017 and is headquartered in Oakville, Canada.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
Oscillators
Neutral
Summary
Neutral
Summary
Neutral
Summary
Neutral
Moving Averages
Neutral
Moving Averages
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of PRM.PR.A is 10.27 CAD — it hasn't changed in the past 24 hours. Watch Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 stocks are traded under the ticker PRM.PR.A.
PRM.PR.A stock has fallen by −0.19% compared to the previous week, the month change is a −0.96% fall, over the last year Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 has showed a 1.99% increase.
PRM.PR.A reached its all-time high on Jul 4, 2019 with the price of 11.44 CAD, and its all-time low was 8.72 CAD and was reached on Mar 20, 2020. View more price dynamics on PRM.PR.A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PRM.PR.A stock is 0.00% volatile and has beta coefficient of −0.04. Track Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 stock price on the chart and check out the list of the most volatile stocks — is Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 there?
Yes, you can track Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 financials in yearly and quarterly reports right on TradingView.
PRM.PR.A net income for the last half-year is 1.87 M CAD, while the previous report showed 4.89 M CAD of net income which accounts for 0.00% change. Track more Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 financial stats to get the full picture.
Yes, PRM.PR.A dividends are paid quarterly. The last dividend per share was 0.13 CAD. As of today, Dividend Yield (TTM)% is 8.39%. Tracking Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 dividends might help you take more informed decisions.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 EBITDA is 7.41 M CAD, and current EBITDA margin is 346.00%. See more stats in Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 financial statements.
Like other stocks, PRM.PR.A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 stock shows the buy signal. See more of Big Pharma Split Corp 5 % Cum Pfd Registered 2017-31.12.22 technicals for a more comprehensive analysis.